Cardiovascular Regenerative Medicine
Cardiovascular Regenerative Medicine
批准号:
8663728
负责人:
Douglas E Vaughan
金额:
$9.72万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-07 至 2016-04-30
关键词:
AgingAmputationAnimalsAutologousBeliefBiologyCD34 geneCardiovascular DiseasesCardiovascular systemCell SeparationCell TherapyCell physiologyCellsChest PainChronicClinical TrialsCollaborationsDataDefectDiabetes MellitusDiseaseDoctor of MedicineDoctor of PhilosophyEnvironmentEpigenetic ProcessExercise ToleranceFibrosisFunctional disorderGoalsHistologyHumanIndividualIschemiaKnowledgeLimb structureMethodsMitochondriaMyocardialOperative Surgical ProceduresOutcomePatientsPeptidesPlasminogen Activator Inhibitor 1Principal InvestigatorRecruitment ActivityRefractoryRegenerative MedicineRoleSafetyStem cellsTherapeuticTherapeutic Usesbasedesignimprovedinterestmembermolecular imagingnanomaterialsnovelphase 3 studyprogramsrepaired
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Recent data, generated as the result of a decade long effort by the Program PI to develop endothelial progenitor cell based therapeutics, provides evidence for the safety and efficacy of autologous progenitor cells for treatment of myocardial and limb ischemia. Specifically two recent human clinical trials have both yielded evidence that autologous human CD34+ cells improve outcome in patients with chronic, refractory ischemia: patients with intractable angina had significant reductions in chest pain and improved exercise tolerance, while patients with critical limb ischemia had reduced amputation rates. While we acknowledge that the final proof of progenitor cell based therapies in phase III studies is forthcoming, it is our belief that the available evidence for bioactivity and potential therapeutic utility of cell based therapy is substantial enough to justify efforts to augment their efficacy by exploiting our knowledge about their biology and further exploring mechanisms that may enhance their safety and therapeutic utility. The overarching goal of this PPG is to advance the therapeutic use of endothelial progenitor cells for the treatment of cardiovascular diseases. This objective will be achieved in the Program by four individual Projects that investigate certain mechanisms of progenitor cell fate, function and dysfunction, and explore novel, nanomaterial based methods to enhance their therapeutic application and by taking advantage of strategically designed Cores that will support each Project. Project 1: Enhancing Progenitor Cell Function using Bioactive Peptide Amphiphiles (Douglas W. Losordo, M.D. and Samuel Stupp Ph.D., Co-I) Project 2: Role of PAI-1 in Cardiovascular Repair and Fibrosis (Douglas E. Vaughan, M.D., PI) Project 3: Characterization of mitochondrial defects in EPCs in diabetes and aging (Hossein Ardehali, M.D., Ph.D., PI) Project 4: Epigenetic modulation of Endothelial Progenitor Cells for Cardiomyogenesis (Raj Kishore, Ph.D., PI) Core A: Small Animal Surgery and Histology (Tsutomu Kume, Ph.D., PI) Core B: Advanced Molecular Imaging (Tom Meade, Ph.D., PI) Core C: FACS Analysis and Cell Sorting (Harris Perlman, Ph.D., PI) Core D; Administrative Core (Douglas Losordo, M.D., PI)
PROJECT 1: Peptide Amphiphiles to Augment Progenitor Cell Therapies (Losordo, Douglas W.)
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Evolutionary Advantage of Heterozygous PAI-1 Deficiency in Humans
-
批准号:10686583
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2022
-
负责人:Douglas E Vaughan
-
依托单位:
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology
-
批准号:10402774
-
项目类别:
-
资助金额:$67.08万
-
财政年份:2019
-
负责人:Douglas E Vaughan
-
依托单位:
Spontaneous cardiac fibrosis in PAI-1-deficient mice and men: A rare mutation informs a common molecular pathophysiology
-
批准号:9908161
-
项目类别:
-
资助金额:$67.14万
-
财政年份:2019
-
负责人:Douglas E Vaughan
-
依托单位:
Cardiovascular Regenerative Medicine
-
批准号:8661256
-
项目类别:
-
资助金额:$210.66万
-
财政年份:2011
-
负责人:Douglas E Vaughan
-
依托单位:
Cardiovascular Regenerative Medicine
-
批准号:8464219
-
项目类别:
-
资助金额:$199.86万
-
财政年份:2011
-
负责人:Douglas E Vaughan
-
依托单位:
Cardiovascular Regenerative Medicine
-
批准号:8329605
-
项目类别:
-
资助金额:$215.67万
-
财政年份:2011
-
负责人:Douglas E Vaughan
-
依托单位:
CARDIOVASCULAR CORE
-
批准号:7638639
-
项目类别:
-
资助金额:$25.66万
-
财政年份:2008
-
负责人:Douglas E Vaughan
-
依托单位:
Cell Therapy for Improving Cardiac Function
-
批准号:7212901
-
项目类别:
-
资助金额:$55.41万
-
财政年份:2007
-
负责人:Douglas E Vaughan
-
依托单位:
CARDIOVASCULAR CORE
-
批准号:7560713
-
项目类别:
-
资助金额:$26.18万
-
财政年份:2007
-
负责人:Douglas E Vaughan
-
依托单位:
DEFINING STRATEGIES FOR IMPROVING ENDOTHELIAL/FIBRINOLYTIC DYFUNCTION IN OBESITY
-
批准号:7605664
-
项目类别:
-
资助金额:$0.97万
-
财政年份:2006
-
负责人:Douglas E Vaughan
-
依托单位:
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 IN OBESE POPULATION
-
批准号:7731493
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2006
-
负责人:Douglas E Vaughan
-
依托单位:
DEFINING STRATEGIES FOR IMPROVING ENDOTHELIAL/FIBRINOLYTIC DYFUNCTION IN OBESITY
-
批准号:7731488
-
项目类别:
-
资助金额:$0.05万
-
财政年份:2006
-
负责人:Douglas E Vaughan
-
依托单位:
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 IN OBESE POPULATION
-
批准号:7605669
-
项目类别:
-
资助金额:$0.47万
-
财政年份:2006
-
负责人:Douglas E Vaughan
-
依托单位:
SCCOR in Hemostatic and Thrombotic Diseases
-
批准号:6952044
-
项目类别:
-
资助金额:$317.03万
-
财政年份:2006
-
负责人:Douglas E Vaughan
-
依托单位:
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 LEVELS IN AN OBESE POPULATION
-
批准号:7375635
-
项目类别:
-
资助金额:$0.46万
-
财政年份:2005
-
负责人:Douglas E Vaughan
-
依托单位:
HRT AND PROTEIN EXPRESSION IN POSTMENOPAUSAL WOMEN
-
批准号:7375686
-
项目类别:
-
资助金额:$0.17万
-
财政年份:2005
-
负责人:Douglas E Vaughan
-
依托单位:
THE EFFECTS OF PENTOXIFYLLINE ON PAI-1 LEVELS IN AN OBESE POPULATION
-
批准号:7207291
-
项目类别:
-
资助金额:$3.13万
-
财政年份:2004
-
负责人:Douglas E Vaughan
-
依托单位:
The Effects of Pentoxifylline on PAI-1 Levels in an Obese Population
-
批准号:7041467
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2003
-
负责人:Douglas E Vaughan
-
依托单位:
Tissue ACE and Fibrinolytic Balance
-
批准号:7041412
-
项目类别:
-
资助金额:$5.83万
-
财政年份:2003
-
负责人:Douglas E Vaughan
-
依托单位:
PAI-1 and Arterial Thrombosis: Models and Mechanisms
-
批准号:6930306
-
项目类别:
-
资助金额:$30.42万
-
财政年份:2000
-
负责人:Douglas E Vaughan
-
依托单位:
海外基金